The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Expected Market Size Of The Entyvio Market In 2026 And How Much Will It Reach By 2030?
Historical expansion was largely due to the drawbacks of traditional immunosuppressive treatments, a growing occurrence of inflammatory bowel disease, the impressive clinical effectiveness of vedolizumab, the widespread acceptance of biologics by gastroenterologists, and regulatory clearances for both ulcerative colitis (UC) and Crohn’s disease (CD).
The anticipated growth during the forecast period is due to several factors, including the increasing global prevalence of IBD, the expansion of treatments into earlier lines, better diagnostic rates, enhanced access to biologic therapies, and a strong focus on long-term disease management.
Key trends observed in the forecast period encompass the rising adoption of gut-selective biologic therapies, their increasing use in moderate to severe IBD, a growing preference for targeted integrin inhibition, the broader application of long-term maintenance therapy, and a heightened emphasis on safety compared to systemic immunosuppressants.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19901&type=smp
Which Core Factors Are Supporting The Expansion Of The Entyvio Market?
The increasing occurrence of inflammatory bowel disease (IBD) is expected to fuel the expansion of the entyvio market moving forward. IBD encompasses a group of chronic, recurrent inflammatory conditions of the gastrointestinal (GI) tract, distinguished by immune system imbalance, which leads to sustained inflammation and tissue damage. The rising incidence of inflammatory bowel disease is attributed to a combination of genetic susceptibility, environmental factors like diet and urbanization, lifestyle modifications including higher stress, and alterations in gut microbiota influenced by elements such as antibiotic use and reduced contact with natural microbes. Entyvio aids in treating IBD by specifically targeting and blocking the alpha4beta7 integrin, which consequently diminishes the migration of inflammatory cells to the gut. For instance, in June 2024, the Centre for Disease Control and Prevention, a US-based non-profit organization, reported that the prevalence of inflammatory bowel disease (IBD) in the United States ranges from 2.4 to 3.1 million people. Therefore, the growing prevalence of inflammatory bowel disease is a key driver for the entyvio market’s growth.
How Does Segment Analysis Break Down The Entyvio Market Structure?
The entyvio market covered in this report is segmented –
1) By Route Of Administration: Subcutaneous Injection, Intravenous Infusion
2) By Treatment Line: First-Line Therapy, Second-Line Therapy
3) By Indication: Ulcerative Colitis (UC), Crohn’s Disease (CD)
4) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care
What Trends Are Influencing The Entyvio Market Outlook?
Leading companies in the entyvio market are concentrating on developing maintenance therapies to enhance the long-term management of inflammatory bowel disease (IBD). These therapies refer to continuous treatments designed to manage chronic conditions, prevent disease progression, and sustain a stable or improved state of health after achieving initial therapeutic objectives. The goal of these treatments is to lessen the risk of relapses, complications, or symptoms over time, thereby ensuring ongoing disease control and an enhanced quality of life for patients. For instance, in April 2024, Takeda pharmaceutical, a US based pharmaceutical company, received Food and Drug Administration, a US-based federal agency, approval for the subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) following induction therapy with intravenous (IV) Entyvio. This subcutaneous option facilitates self-administration using a pre-filled pen, offering increased convenience for patients to manage their treatment at home subsequent to an initial IV infusion during the induction phase. Clinical studies have demonstrated that Entyvio significantly improves symptoms and induces remission in patients with Crohn’s disease when compared to a placebo.
Who Are The Companies Shaping The Entyvio Market Landscape?
Major companies operating in the entyvio market are Takeda Pharmaceutical Company Limited
Access The Complete Entyvio Market Report:
https://www.thebusinessresearchcompany.com/report/entyvio-global-market-report
Which Region Stands As The Largest Contributor To The Entyvio Market?
North America was the largest region in the Entyvio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the entyvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model